Analysts Boost Inventiva Price Target Amid Optimism for MASH Market and Pipeline Progress

Analysts have maintained their fair value estimate for Inventiva at $7.95, citing continued optimism around forthcoming Phase 3 data. There is also a growing consensus on the promising outlook for lanifibranor in the MASH market.

Analysts have raised their average price target for Inventiva from $9 to $13 per share, citing increased optimism for the Metabolic-Associated Steatohepatitis market as well as a larger anticipated target patient population. Analyst Commentary Bullish Takeaways Bullish analysts have increased their price targets, reflecting heightened enthusiasm for the Metabolic-Associated Steatohepatitis market and an anticipated expansion in the eligible patient population.

Analysts have increased their fair value estimate for Inventiva from $6.45 to $7.95 per share. They cited greater conviction in revenue growth potential and profit margins for its lead asset in the metabolic disease market.

AnalystConsensusTarget has decreased revenue growth from -2.0% to -0.5% and increased discount rate from 6.4% to 7.0%.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has decreased revenue growth from 57.8% to -2.0%, increased profit margin from 15.6% to 17.6%, increased future PE multiple from 149.7x to 363.5x and decreased shares outstanding growth rate from 0.3% to 0.1%.